HK Stock MarketDetailed Quotes

00867 CMS

Watchlist
  • 8.710
  • +0.180+2.11%
Not Open Apr 24 16:08 CST
21.25BMarket Cap12.15P/E (TTM)

About CMS Company

CMS is an open platform enterprise that links pharmaceutical innovation and commercialization, controls product life cycle management, and is committed to providing competitive products and services to meet unmet medical needs. Kang Zhe Pharmaceutical Co., Ltd. focuses on the innovative products of the global initiative (FIC) and the best of its kind (BIC). It has a rich innovation pipeline with differentiated layout, high innovation level and great market potential. Kangzhe Pharmaceutical Co., Ltd. focuses on the specialist field, has proven commercialization capabilities, extensive channel network and expert resources, and the core products on sale have gained a leading academic and market position. Focus on the in-depth development of superior specialist areas, expand the boundary, in order to consolidate the competitiveness of cardio-cerebrovascular / digestive business, and operate the skin and ophthalmology business independently to improve scale efficiency. At the same time, the business territory is expanded to the Southeast Asian market, making great efforts to become the "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, and to promote the high-quality, sustained and healthy development of Kangzhe Pharmaceutical Industry.

Company Profile

Symbol00867
Company NameCMS
ISINKYG211081248
Listing DateSep 28, 2010
Issue Price5.06
Shares Offered200.00M share(s)
FoundedDec 18, 2006
Registered AddressCayman Islands
Chairmangang lin
Secretarysanyan wu
Audit InstitutionDeloitte Guan Huang Chen Fang Certified Public Accountants
Company CategoryOther
Registered OfficePO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands
Head Office and Principal Place of BusinessRoom 2106, 21st floor, Hong Kong Transport Building, 510 King's Road, North Point, Hong Kong
Fiscal Year Ends12-31
Employees6141
MarketHong Kong motherboard
Phone(86)75582416868
Fax(852)23891320
Emailinfo@cms.net.cn
Business Kangzhe Pharmaceutical is an open platform enterprise linking pharmaceutical innovation and commercialization to control the full life cycle management of products. It is committed to providing competitive products and services to meet unmet medical needs. Kangzhe Pharmaceutical focuses on the world's first (FIC) and best-in-class (BIC) innovative products, and has laid out a rich innovation pipeline with differentiation, high innovation levels, and great market potential. Kangzhe Pharmaceutical focuses on specialized fields, has proven commercialization capabilities, extensive channel networks and expert resources, and the core products on sale have gained leading academic and market positions. Continue to develop in depth and expand borders around dominant specialty fields to consolidate the competitiveness of cardiovascular and digestive businesses, and operate dermatology and ophthalmology businesses independently to improve scale efficiency. At the same time, the business area expanded to the Southeast Asian market, focusing on becoming a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, helping Kangzhe Pharmaceutical develop high-quality, sustainable and healthy.

Company Executives

  • Name
  • Position
  • Salary
  • gang lin
  • Presidencies, CEOs, President, CEO, Executive Director, Nomination Committee Members, Authorized Representative
  • 6.19M
  • yanling chen
  • VP, Executive Director, Chief Financial Officer
  • 4.89M
  • hongbing chen
  • Non-executive Directors
  • 5.18M
  • chuangshun liang
  • Independent Non-Executive Director, Remuneration Committee Chairman, Nomination Committee Members, Audit Committee Members
  • 330.00K
  • ying luo
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Audit Committee Members, Remuneration Committee Members
  • 330.00K
  • zheng feng
  • Independent Non-Executive Director, Chairman of the Audit Committee, Nomination Committee Members, Remuneration Committee Members
  • 330.00K
  • lieyi ma
  • General Manager of the Group's Business Operation Center
  • --
  • qingfu jiang
  • General Manager of the Group's Cardiovascular/Digestive Business (Shenzhen Kangzhe)
  • --
  • yufang li
  • General Manager of the Group's Financial Center
  • --
  • jie fan
  • Deputy General Manager, General Manager of Out-of-hospital Channel and Supply Chain Center
  • --
  • ping cai
  • Deputy General Manager, General Manager of Strategic Market Center
  • --
  • anjun huang
  • General Manager of the Group's Dermatology and Aesthetic Business (Kangzhe Beauty)
  • --
  • huaizheng peng
  • Chief Commercial Officer of the Group
  • --
  • fei jiang
  • Chief Investment Officer of the Group (Greater China)
  • --
  • James Stearns
  • Group Chief Investment Officer (Europe and America)
  • --
  • linlang wang
  • General Manager of the Group's ophthalmology business (Kangzhe Weisheng)
  • --
  • sanyan wu
  • Director of Legal Affairs, Authorized Representative, Company Secretary
  • --

Market Insights

Warren Buffett Portfolio Warren Buffett Portfolio

Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.

Unlock Now

Discussing

2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current Show More